BioSpace News Archive

ICON plc, a global provider of outsourced drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health organisations, announced that all resolutions at the ICON Extraordinary General Meeting of the Company held on June 15, 2021 were all duly passed by shareholders.

PTC Therapeutics, Inc. announced that on June 11, 2021 it approved non-statutory stock options to purchase an aggregate of 118,350 shares of its common stock and 30,835 restricted stock units, each representing the right to receive one share of its common stock upon vesting, to 66 new employees.

Bicycle Therapeutics plc today announced an update regarding shareholder attendance at its 2021 Annual General Meeting (the “AGM”) to be held on June 28, 2021.

MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), today announced publication of its peer-reviewed study in the Journal of Investigative Dermatology (JID) Innovations, addressing the potential benefit of MIMEDX Purion processed dehydrated human amnion/chorion membrane (dHACM) to combat complications stemming from excessive fibrosis,

Braeburn announces that today the New Drug Application (NDA) for BRIXADI was resubmitted to the U.S. Food and Drug Administration (FDA).

MedX Health Corporation a global leader in teledermatology, is pleased to announce a distribution agreement with VidaCeuticals Health Products Inc. that will see MedX’s integrated skin assessment teledermatology platform offered at four clinics in Ontario beginning in late June, with plans for a broader market roll-out in Canada and the United States later this year.

AVITA Medical, Inc. today announced preliminary, unaudited financial results for the fiscal fourth quarter 2021.

Camurus AB (NASDAQ STO: CAMX) today announced that its US licensee Braeburn has resubmitted the New Drug Application (NDA) for Brixadi 1 (buprenorphine) extended-release weekly and monthly injections for the treatment of moderate to severe opioid use disorder to the US Food and Drug Administration (FDA).

Growing need to monitor chronic inflammatory conditions, increasing CVD in geriatric population, and rising use of C-reactive protein in clinical diagnostics are key factors driving market growth.

Rising prevalence of disruptive behavior disorders globally and increasing demand for treatment of same are expected to fuel market growth.